Who are NSAID therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NSAID (Ketorolac/Ibuprofen), NSAID's, Diclofenac hydroxyethylpyrrolidine, Tinoridine HCl, Oral tablets of Alphintern®, Metamizole Sodium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nsaid-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

NSAID therapy — Competitive Intelligence Brief

NSAID therapy (NSAID therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-steroidal anti-inflammatory drug (NSAID). Area: Pain Management, Rheumatology, Cardiovascular.

marketed Non-steroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Pain Management, Rheumatology, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

NSAID therapy (NSAID therapy) — Rabin Medical Center. NSAIDs inhibit cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
NSAID therapy TARGET	NSAID therapy	Rabin Medical Center	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
NSAID (Ketorolac/Ibuprofen)	NSAID (Ketorolac/Ibuprofen)	Thomas Jefferson University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
NSAID's	NSAID's	Saglik Bilimleri Universitesi Gulhane Tip Fakultesi	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Diclofenac hydroxyethylpyrrolidine	Diclofenac hydroxyethylpyrrolidine	IBSA Institut Biochimique SA	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Tinoridine HCl	Tinoridine HCl	Takeda	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Oral tablets of Alphintern®	Oral tablets of Alphintern®	Ain Shams University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-2
Metamizole Sodium	Metamizole Sodium	Insel Gruppe AG, University Hospital Bern	marketed	Non-steroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-steroidal anti-inflammatory drug (NSAID) class)

Ain Shams University · 1 drug in this class
IBSA Institut Biochimique SA · 1 drug in this class
Insel Gruppe AG, University Hospital Bern · 1 drug in this class
Pfizer · 1 drug in this class
Rabin Medical Center · 1 drug in this class
Saglik Bilimleri Universitesi Gulhane Tip Fakultesi · 1 drug in this class
Shijiazhuang Yiling Pharmaceutical Co. Ltd · 1 drug in this class
Takeda · 1 drug in this class
Thomas Jefferson University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NSAID therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/nsaid-therapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab